US20110212885A1 - Ophthalmic and contact lens solutions containing peptides as preservative - Google Patents
Ophthalmic and contact lens solutions containing peptides as preservative Download PDFInfo
- Publication number
- US20110212885A1 US20110212885A1 US13/037,802 US201113037802A US2011212885A1 US 20110212885 A1 US20110212885 A1 US 20110212885A1 US 201113037802 A US201113037802 A US 201113037802A US 2011212885 A1 US2011212885 A1 US 2011212885A1
- Authority
- US
- United States
- Prior art keywords
- solution
- preservative
- seq
- bis
- tris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- GGMSNXDNHUPSJJ-UHFFFAOYSA-N C.C.C.CCNC(=N)NC(=N)NCC Chemical compound C.C.C.CCNC(=N)NC(=N)NCC GGMSNXDNHUPSJJ-UHFFFAOYSA-N 0.000 description 2
- XAZVWAVHXCKIFU-UHFFFAOYSA-N CN.CNC(=N)NC#N Chemical compound CN.CNC(=N)NC#N XAZVWAVHXCKIFU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/141—Biguanides, e.g. chlorhexidine
- A61L12/142—Polymeric biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
Definitions
- the present invention relates to the field of ophthalmic solutions and their uses.
- the invention relates to contact lens cleaning solutions, contact lens rinsing and storing solutions, solutions to deliver active pharmaceutical agents to the eye, solutions for disinfecting ophthalmic devices and the like.
- the present invention relates to the field of ophthalmic solutions and especially to the aspects of preservative efficacy and comfort after prolonged use. These ophthalmic solutions have been used for some period of time and are available as over the counter products. Solutions that are used in direct contact with corneal tissue such as the delivery of active pharmaceutical agent to the eye, or indirectly, such as the cleaning, conditioning or storage of devices that will come in contact with corneal tissue, such as contact lenses, there is a need to insure that these solution do not introduce sources of bacterial or other microbial infection. Thus preservatives are included to reduce the viability of microbes in the solution and to lessen the chance of contamination of the solution by the user since many of the solutions are bought, opened, used, sealed and then reused.
- preservative agents include polyhexamethylene biguanide (phmb), PolyquadTM, chlorhexidine, and benzalkonium chloride, and the like, all of which at some concentration irritate corneal tissue and lead to user discomfort. Therefore, a solution that employs a given amount of a preservative agent, but which is made more effective by addition of an agent that is not a preservative agent would be desired.
- the present invention relates to improved ophthalmic solutions that employ certain amphipathic peptides disclosed in U.S. Pat. Nos. 5,968,904; 6,001,805 and 6,191,110 in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses.
- Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.
- amphipathic in application to a peptide or class of peptides means peptide(s) which contain hydrophilic and hydrophobic amino acid moieties (side chains) which are oriented in relation to one another so that the peptide(s) have discrete hydrophilic and hydrophobic faces or regions defined by a multiplicity of the respective hydrophilic and hydrophobic side chains.
- the hydrophobic amino acid side chains are oriented on one face of the alpha helix while the hydrophilic amino acid side chains are oriented on the other face of the alpha helix.
- the peptide is amphipathic and exists (in solution) in a beta-pleated sheet conformation, the peptide likewise exhibits hydrophobic and hydrophilic faces deriving from the alignment of the oriented amino acid side chains of the molecule.
- defensin-class peptide means either a natural defensin peptide which is provided in isolated form as an active ingredient of the composition employed for wound healing treatment in accordance with U.S. Pat. No. 6,191,110, or else a synthetic peptide which is homologous to the natural defensin peptide, containing between 17 and 39 amino acids along its length, and forming amphipathic beta-pleated sheets in solution.
- amphipathic peptides may be effectively utilized in the broad practice of the present invention, including, but not limited to, natural and synthetic melittin-class, cecropin-class, magainin-class, and defensin-class peptides.
- beta pleated sheet conformation of peptides potentially usefully employed in the broad practice of the present invention may be readily determined by the circular dichroism technique described in Proteins, Creighton, Thomas E., W.H. Freeman & Co., New York (1984), pp. 179-182.
- solutions specifically described herein have 0.0001 to about 3 percent of the peptide in combination with other active ingredients useful in ophthalmic solutions such as buffers, preservatives, surfactants, and antimicrobial agents.
- the preservatives that are specifically useful are cationic polymeric preservatives such as polyhexamethylene biguanide (phmb), PolyquadTM, chlorhexidne, and benzalkonium chloride, as well as other cationic preservatives that may prove useful in the present invention as well.
- the cationic preservatives are used at effective amounts as preservatives, and in the instance of PHMB from 0.0001 percent by weight to higher levels of about 0.01 weight percent.
- the cationic polymeric preservative includes polymeric biguanides such as polymeric hexamethylene biguanides (PHMB), and combinations thereof.
- PHMB polymeric hexamethylene biguanides
- Z is an organic divalent bridging group which may be the same or different throughout the polymer, n is on average at least 3, preferably on average 5 to 20, and X 1 and X 2 are
- water-soluble polymeric biguanides will have number average molecular weights of at least 1,000 and more preferably will have number average molecular weights from 1,000 to 50,000.
- Suitable water-soluble salts of the free bases include, but are not limited to hydrochloride, borate, acetate, gluconate, sulfonate, tartrate and citrate salts.
- polystyrene foam Most preferred are the polymeric hexamethylene biguanides, commercially available, for example, as the hydrochloride salt from Zeneca (Wilmington, Del.) under the trademark CosmocilTM CQ. Such polymers and water-soluble salts are referred to as polyhexamethylene (PHMB) or polyaminoptopyl biguanide (PAPB).
- PHMB polyhexamethylene
- PAPB polyaminoptopyl biguanide
- polyhexamethylene biguanide is meant to encompass one or more
- biguanides have the following formula: wherein Z, X 1 and X 2 are as defined above and n is from 1 to 500.
- the predominant compound falling within the above formula may have different X 1 and X 2 groups or the same groups, with lesser amounts of other compounds within the formula.
- Such compounds are known and are disclosed in U.S. Pat. No. 4,758,595 and British Patent 1,432,345, which patents are hereby incorporated.
- the water-soluble salts are compounds where n has an average value of 2 to 15, most preferably 3 to 12.
- the formulations may also include buffers such as phosphates, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, MES, MOPS, PIPES, TAPS, TES, Glycine, and Tricine
- buffers such as phosphates, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, MES, MOPS, PIPES, TAPS, TES, Glycine, and Tricine
- Surfactants that might be employed include polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils, but preferrably the polyethoxylated castor oils. These surfactants are commercially available.
- the polyethoxylated castor oils are sold by BASF under the trademark Cremaphor.
- Inositol, mannitol, sorbitol, sucrose, dextrose, glycerin, propylene glycol and the other agents used in the present invention are all commercially available, and well enough understood to be formulated into products within the scope of the invention by those skilled in the art.
- solutions of the present invention may contain other additives including but not limited to buffers, tonicity agents, demulcents, wetting agents, preservatives, sequestering agents (chelating agents), surface active agents, and enzymes.
- chelating agent preferably disodium EDTA
- additional microbicide preferably 0.00001 to 0.1 or 0.00001 to 0.01
- weight percent chelating agent preferably disodium EDTA
- additional microbicide preferably 0.00001 to 0.1 or 0.00001 to 0.01
- weight percent polyhexamethylene biquanide PHMB0, N-alkyl-2-pyrrolidone, chlorhexidine, polyquaternium-1, hexetidine, bronopol, alexidine, low concentrations of hydrogen peroxide, and ophthalmologically acceptable salts thereof
- Ophthalmologically acceptable chelating agents useful in the present invention include amino carboxylic acid compounds or water-soluble salts thereof, including ethylenediaminetetraacetic acid, nitrilotriacetic acid, diethylenetriamine pentaacetic acid, hydroxyethylethylenediaminetriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, ethylene glycol bis(beta-aminoethyl ether) in N,N,N′,N′ tetraacetic acid (EGTA), aminodiacetic acid and hydroxyethylamino diacetic acid.
- These acids can be used in the form of their water soluble salts, particularly their alkali metal salts.
- Especially preferred chelating agents are the di-, tn- and tetra-sodium salts of ethylenediaminetetraacetic acid (EDTA), most preferably disodium EDTA (Disodium Edetate).
- citrates and polyphosphates can also be used in the present invention.
- the citrates which can be used in the present invention include citric acid and its mono-, di-, and tri-alkaline metal salts.
- the polyphosphates which can be used include pyrophosphates, triphosphates, tetraphosphates, trimetaphosphates, tetrametaphosphates, as well as more highly condensed phosphates in the form of the neutral or acidic alkali metal salts such as the sodium and potassium salts as well as the ammonium salt.
- the pH of the solutions should be adjusted to be compatible with the eye and the contact lens, such as between 6.0 to 8.0, preferably between 6.8 to 7.8 or between 7.0 to 7.6. Significant deviations from neutral (pH 7.3) will cause changes in the physical parameters (i.e. diameter) in some contact lenses. Low pH (pH less than 5.5) can cause burning and stinging of the eyes, while very low or very high pH (less than 3.0 or greater than 10) can cause ocular damage.
- the additional preservatives employed in the present invention are known, such as polyhexamethylene biguanide, N-alkyl-2-pyrrolidone, chlorhexidine, polyhexamethylenebiguanide, alexidine, polyquaternium-1, hexetidine, bronopol and a very low concentration of hydrogen peroxide, e.g., 30 to 200 ppm.
- solutions of the invention are compatible with both rigid gas permeable and hydrophilic contact lenses during storage, cleaning, wetting, soaking, rinsing and disinfection.
- a typical aqueous solution of the present invention may contain additional ingredients which would not affect the basic and novel characteristics of the active ingredients described earlier, such as tonicity agents, surfactants and viscosity inducing agents, which may aid in either the lens cleaning or in providing lubrication to the eye.
- Suitable tonicity agents include sodium chloride, potassium chloride, glycerol or mixtures thereof.
- the tonicity of the solution is typically adjusted to approximately 240-310 milliosmoles per kilogram solution (mOsm/kg) to render the solution compatible with ocular tissue and with hydrophilic contact lenses.
- the solution contains 0.01 to 0.2 weight percent sodium chloride. The important factor is to keep the concentrations of such additives to a degree no greater than that would supply a chloride concentration of no greater than about 0.2 mole percent.
- Suitable viscosity inducing agents can include lecithin or the cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose and methylcellulose in amounts similar to those for surfactants, above.
- Peptides were tested using a conventional Disinfection Efficacy antimicrobial assay (ISO 14729), commonly used in evaluating biocidal efficacy of preservatives for use in contact lens care solutions. Briefly, a known concentration of organisms are inoculated into the test solution, and allowed to incubate for a given amount of time, after which they are neutralized to inactivate the preservative. Samples are serially diluted and plated in duplicate onto petri plates onto which growth medium is poured. The plates are incubated at 35° C. (bacteria) or 25° C. (yeast and molds) for 48 hours.
- ISO 14729 Disinfection Efficacy antimicrobial assay
- the average number of colony forming units is determined on countable plates (the dilution at which between 30 to 300 cfu/plate are observed, except when colonies are observed only on the ⁇ 1 dilution plates).
- the log reduction resulting from exposure to the test solution is calculated based on the growth of positive controls plated simultaneously. Recovery controls, to confirm that the test solution is neutralized, and viability controls are also plated.
- SEQ ID NO. 3 P-113 was screened for anti-candidal activity. Of the organism routinely used for preservative efficacy testing, Candida albicans is often the most resistant.
- Candida albicans ATCC 10231
- ATCC 102311 Stock cultures were incubated and prepared to result in cell suspensions containing between 10 7 and 10 8 cfu/mL.
- the Disinfection Efficacy test as described above, was used, with the following modification: Since the standard Dey-Engley broth used to neutralize preservatives was not necessarily expected to neutralize the peptide, 0.1% sodium laurel sulfate (SLS) was added to the neutralization solution. Controls confirmed that this was effective in neutralizing the peptide test solution.
- SLS sodium laurel sulfate
- SEQ ID NO. 3 SEQ ID NO. 4
- SEQ ID NO. 2 D2A21
- the Disinfection Efficacy test was used with the following organisms: Staphylococcus aureus (ATCC 6538), Pseudomonas aeruginosa (ATCC 9027), Serratia marcesens (ATCC 13880), Candida albicans (ATCC 10231), and Fusarium solani (ATCC 36031).
- the peptides were diluted in water at a concentration of 100 ug/mL (adjusted for purity).
- Organism cultures were prepared to result in an inoculum concentration between 10 7 and 10 8 cfu/mL.
- the test solutions were inoculated for a 1 hour and a 3 hour exposure period, neutralized with DEB with 0.1% SLS added, and plated in duplicate.
- SEQ ID NO. 3 The selectivity of SEQ ID NO. 3 on Candida and Pseudomonas may prove useful for certain applications. There was no significant difference between the SEQ ID NO. 3 (L) and SEQ ID NO. 4. The broad spectrum efficacy of SEQ ID NO. 1 and SEQ ID NO. 2 indicates that these peptides may prove extremely useful for treating a wide variety of ocular infections, and in particular, contact-lens associated keratitis.
- the Disinfection Efficacy test was used as in experiment 2 using Staphylococcus aureus and Pseudomonas aeruginosa .
- the peptides were diluted in water at concentrations of 100, 33.3, 10, 3.33, and 1 ug/mL.
- the test solutions were inoculated for 1 hour, neutralized, and plated in duplicate.
- Test Solution Conc. cfu average Average Log Microorganism ID ( ⁇ g/mL) dilution (average) cfu/mL Reduction S. aureus Positive ⁇ 4 36 3.60E+05 ATCC 6538
- Control T 1 hr D4E1 100 ⁇ 1 0 0.00E+00 >4.86 33 ⁇ 1 0 0.00E+00 >4.86 10 ⁇ 1 0 0.00E+00 >4.86 3.33 ⁇ 1 0 0.00E+00 >4.86 1 ⁇ 1 1 5.00E+00 4.86 D2A21 100 ⁇ 1 0 0.00E+00 >4.86 33 ⁇ 1 0 0.00E+00 >4.86 10 ⁇ 1 1 1.00E+01 4.56 3.33 ⁇ 1 0 0.00E+00 >4.86 1 ⁇ 1 112 1.12E+03 2.51 P-113 100 ⁇ 4 38 3.80E+05 ⁇ 0.02 33 ⁇ 4 34 3.40E+05 0.03 10 ⁇ 3 202 2.02E+05 0.25
Abstract
A method and a contact lens solution comprising 0.001 to 10 weight percent or a preservative enhancer chosen from the group consisting of: SEQ ID NO.1 and SEQ ID NO. 2; and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
Description
- This application is a continuation of applicant's co-pending patent application U.S. Ser. No. 10/593,352, filed Sep. 19, 2006 and claims priority to and the benefit of PCT application number PCT/US04/011575, filed Apr. 15, 2004, and U.S. provisional patent application Ser. No. 60/462,940, filed Apr. 15, 2003, which are incorporated herein by reference in their entirety.
- This application refers to a “Sequence Listing” listed below, which is provided as a paper copy and a computer readable form labeled “Sequence listing.txt” (1,422 bytes, created on Oct. 18, 2007, 11:02:13 AM), which is incorporated herein by reference in its entirety.
- The present invention relates to the field of ophthalmic solutions and their uses. In particular the invention relates to contact lens cleaning solutions, contact lens rinsing and storing solutions, solutions to deliver active pharmaceutical agents to the eye, solutions for disinfecting ophthalmic devices and the like.
- The present invention relates to the field of ophthalmic solutions and especially to the aspects of preservative efficacy and comfort after prolonged use. These ophthalmic solutions have been used for some period of time and are available as over the counter products. Solutions that are used in direct contact with corneal tissue such as the delivery of active pharmaceutical agent to the eye, or indirectly, such as the cleaning, conditioning or storage of devices that will come in contact with corneal tissue, such as contact lenses, there is a need to insure that these solution do not introduce sources of bacterial or other microbial infection. Thus preservatives are included to reduce the viability of microbes in the solution and to lessen the chance of contamination of the solution by the user since many of the solutions are bought, opened, used, sealed and then reused.
- State of the art preservative agents include polyhexamethylene biguanide (phmb), Polyquad™, chlorhexidine, and benzalkonium chloride, and the like, all of which at some concentration irritate corneal tissue and lead to user discomfort. Therefore, a solution that employs a given amount of a preservative agent, but which is made more effective by addition of an agent that is not a preservative agent would be desired.
- The present invention relates to improved ophthalmic solutions that employ certain amphipathic peptides disclosed in U.S. Pat. Nos. 5,968,904; 6,001,805 and 6,191,110 in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.
- As used herein, the term “amphipathic” in application to a peptide or class of peptides means peptide(s) which contain hydrophilic and hydrophobic amino acid moieties (side chains) which are oriented in relation to one another so that the peptide(s) have discrete hydrophilic and hydrophobic faces or regions defined by a multiplicity of the respective hydrophilic and hydrophobic side chains. For example, when the peptide is in an amphipathic alpha-helix conformation, the hydrophobic amino acid side chains are oriented on one face of the alpha helix while the hydrophilic amino acid side chains are oriented on the other face of the alpha helix. When the peptide is amphipathic and exists (in solution) in a beta-pleated sheet conformation, the peptide likewise exhibits hydrophobic and hydrophilic faces deriving from the alignment of the oriented amino acid side chains of the molecule.
- As used herein, the term “defensin-class peptide” means either a natural defensin peptide which is provided in isolated form as an active ingredient of the composition employed for wound healing treatment in accordance with U.S. Pat. No. 6,191,110, or else a synthetic peptide which is homologous to the natural defensin peptide, containing between 17 and 39 amino acids along its length, and forming amphipathic beta-pleated sheets in solution.
- A wide variety of amphipathic peptides may be effectively utilized in the broad practice of the present invention, including, but not limited to, natural and synthetic melittin-class, cecropin-class, magainin-class, and defensin-class peptides.
- The beta pleated sheet conformation of peptides potentially usefully employed in the broad practice of the present invention may be readily determined by the circular dichroism technique described in Proteins, Creighton, Thomas E., W.H. Freeman & Co., New York (1984), pp. 179-182.
- The solutions specifically described herein have 0.0001 to about 3 percent of the peptide in combination with other active ingredients useful in ophthalmic solutions such as buffers, preservatives, surfactants, and antimicrobial agents.
- The preservatives that are specifically useful are cationic polymeric preservatives such as polyhexamethylene biguanide (phmb), Polyquad™, chlorhexidne, and benzalkonium chloride, as well as other cationic preservatives that may prove useful in the present invention as well. The cationic preservatives are used at effective amounts as preservatives, and in the instance of PHMB from 0.0001 percent by weight to higher levels of about 0.01 weight percent. Specifically, The cationic polymeric preservative includes polymeric biguanides such as polymeric hexamethylene biguanides (PHMB), and combinations thereof. Such cationic polymeric biguanides, and water-soluble salts thereof, having the following formula:
- wherein Z is an organic divalent bridging group which may be the same or different throughout the polymer, n is on average at least 3, preferably on average 5 to 20, and X1 and X2 are
- One preferred group of water-soluble polymeric biguanides will have number average molecular weights of at least 1,000 and more preferably will have number average molecular weights from 1,000 to 50,000. Suitable water-soluble salts of the free bases include, but are not limited to hydrochloride, borate, acetate, gluconate, sulfonate, tartrate and citrate salts.
- The above-disclosed biguanides and methods of preparation are described in the literature. For example, U.S. Pat. No. 3,428,576 describes the preparation of polymeric biguanides from a diamine and salts thereof and a diamine salt of dicyanimide.
- Most preferred are the polymeric hexamethylene biguanides, commercially available, for example, as the hydrochloride salt from Zeneca (Wilmington, Del.) under the trademark Cosmocil™ CQ. Such polymers and water-soluble salts are referred to as polyhexamethylene (PHMB) or polyaminoptopyl biguanide (PAPB). The term polyhexamethylene biguanide, as used herein, is meant to encompass one or more
- biguanides have the following formula:
wherein Z, X1 and X2 are as defined above and n is from 1 to 500. - Depending on the manner in which the biguanides are prepared, the predominant compound falling within the above formula may have different X1 and X2 groups or the same groups, with lesser amounts of other compounds within the formula. Such compounds are known and are disclosed in U.S. Pat. No. 4,758,595 and British Patent 1,432,345, which patents are hereby incorporated. Preferably, the water-soluble salts are compounds where n has an average value of 2 to 15, most preferably 3 to 12.
- It was found that an unexpected preservative efficacy was displayed when certain peptides were used in conjunction with the cationic preservative. The other components of the solution are used at levels known to those skilled in the art in order to improve the wearability of lenses and when used directly in the eye, to provide increased resistance to infection. These peptides used in ophthalmic solutions increases preservative efficacy in certain formulations, provides increased resistance to infection in corneal tissue, in certain formulations, and improves the quality of tears in certain formulations.
- The formulations may also include buffers such as phosphates, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, MES, MOPS, PIPES, TAPS, TES, Glycine, and Tricine
- Surfactants that might be employed include polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils, but preferrably the polyethoxylated castor oils. These surfactants are commercially available. The polyethoxylated castor oils are sold by BASF under the trademark Cremaphor.
- Inositol, mannitol, sorbitol, sucrose, dextrose, glycerin, propylene glycol and the other agents used in the present invention are all commercially available, and well enough understood to be formulated into products within the scope of the invention by those skilled in the art.
- The solutions of the present invention may contain other additives including but not limited to buffers, tonicity agents, demulcents, wetting agents, preservatives, sequestering agents (chelating agents), surface active agents, and enzymes.
- Other aspects include adding to the solution from 0.001 to 1 weight percent chelating agent (preferably disodium EDTA) and/or additional microbicide, (preferably 0.00001 to 0.1 or 0.00001 to 0.01) weight percent polyhexamethylene biquanide (PHMB0, N-alkyl-2-pyrrolidone, chlorhexidine, polyquaternium-1, hexetidine, bronopol, alexidine, low concentrations of hydrogen peroxide, and ophthalmologically acceptable salts thereof
- Ophthalmologically acceptable chelating agents useful in the present invention include amino carboxylic acid compounds or water-soluble salts thereof, including ethylenediaminetetraacetic acid, nitrilotriacetic acid, diethylenetriamine pentaacetic acid, hydroxyethylethylenediaminetriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, ethylene glycol bis(beta-aminoethyl ether) in N,N,N′,N′ tetraacetic acid (EGTA), aminodiacetic acid and hydroxyethylamino diacetic acid. These acids can be used in the form of their water soluble salts, particularly their alkali metal salts. Especially preferred chelating agents are the di-, tn- and tetra-sodium salts of ethylenediaminetetraacetic acid (EDTA), most preferably disodium EDTA (Disodium Edetate).
- Other chelating agents such as citrates and polyphosphates can also be used in the present invention. The citrates which can be used in the present invention include citric acid and its mono-, di-, and tri-alkaline metal salts. The polyphosphates which can be used include pyrophosphates, triphosphates, tetraphosphates, trimetaphosphates, tetrametaphosphates, as well as more highly condensed phosphates in the form of the neutral or acidic alkali metal salts such as the sodium and potassium salts as well as the ammonium salt.
- The pH of the solutions should be adjusted to be compatible with the eye and the contact lens, such as between 6.0 to 8.0, preferably between 6.8 to 7.8 or between 7.0 to 7.6. Significant deviations from neutral (pH 7.3) will cause changes in the physical parameters (i.e. diameter) in some contact lenses. Low pH (pH less than 5.5) can cause burning and stinging of the eyes, while very low or very high pH (less than 3.0 or greater than 10) can cause ocular damage.
- The additional preservatives employed in the present invention are known, such as polyhexamethylene biguanide, N-alkyl-2-pyrrolidone, chlorhexidine, polyhexamethylenebiguanide, alexidine, polyquaternium-1, hexetidine, bronopol and a very low concentration of hydrogen peroxide, e.g., 30 to 200 ppm.
- The solutions of the invention are compatible with both rigid gas permeable and hydrophilic contact lenses during storage, cleaning, wetting, soaking, rinsing and disinfection.
- A typical aqueous solution of the present invention may contain additional ingredients which would not affect the basic and novel characteristics of the active ingredients described earlier, such as tonicity agents, surfactants and viscosity inducing agents, which may aid in either the lens cleaning or in providing lubrication to the eye. Suitable tonicity agents include sodium chloride, potassium chloride, glycerol or mixtures thereof. The tonicity of the solution is typically adjusted to approximately 240-310 milliosmoles per kilogram solution (mOsm/kg) to render the solution compatible with ocular tissue and with hydrophilic contact lenses. In one embodiment, the solution contains 0.01 to 0.2 weight percent sodium chloride. The important factor is to keep the concentrations of such additives to a degree no greater than that would supply a chloride concentration of no greater than about 0.2 mole percent.
- Suitable viscosity inducing agents can include lecithin or the cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose and methylcellulose in amounts similar to those for surfactants, above.
- Peptides were tested using a conventional Disinfection Efficacy antimicrobial assay (ISO 14729), commonly used in evaluating biocidal efficacy of preservatives for use in contact lens care solutions. Briefly, a known concentration of organisms are inoculated into the test solution, and allowed to incubate for a given amount of time, after which they are neutralized to inactivate the preservative. Samples are serially diluted and plated in duplicate onto petri plates onto which growth medium is poured. The plates are incubated at 35° C. (bacteria) or 25° C. (yeast and molds) for 48 hours. The average number of colony forming units is determined on countable plates (the dilution at which between 30 to 300 cfu/plate are observed, except when colonies are observed only on the −1 dilution plates). The log reduction resulting from exposure to the test solution is calculated based on the growth of positive controls plated simultaneously. Recovery controls, to confirm that the test solution is neutralized, and viability controls are also plated.
- Purpose: SEQ ID NO. 3, P-113 was screened for anti-candidal activity. Of the organism routinely used for preservative efficacy testing, Candida albicans is often the most resistant.
- Method: Candida albicans (ATCC 10231) stock cultures were incubated and prepared to result in cell suspensions containing between 107 and 108 cfu/mL. The Disinfection Efficacy test, as described above, was used, with the following modification: Since the standard Dey-Engley broth used to neutralize preservatives was not necessarily expected to neutralize the peptide, 0.1% sodium laurel sulfate (SLS) was added to the neutralization solution. Controls confirmed that this was effective in neutralizing the peptide test solution. The peptide was tested at a 100 μg/mL concentration in water with a 2 hour exposure time, which resulted in a 2.5 log reduction in Candida.
- Conclusion: In our system, as in the studies performed by Demegen and others, SEQ ID NO. 3, P-113 is effective at killing Candida albicans.
- Purpose: To determine whether 4 distinct distinct peptides, SEQ ID NO. 3 (P-113), SEQ ID NO. 4 (P-113D), SEQ ID NO. 1 (D4E1), and SEQ ID NO. 2 (D2A21) are effective in killing a variety of microorganisms commonly associated with ocular infections and contamination of contact lens solutions.
- Method: The Disinfection Efficacy test was used with the following organisms: Staphylococcus aureus (ATCC 6538), Pseudomonas aeruginosa (ATCC 9027), Serratia marcesens (ATCC 13880), Candida albicans (ATCC 10231), and Fusarium solani (ATCC 36031). The peptides were diluted in water at a concentration of 100 ug/mL (adjusted for purity). Organism cultures were prepared to result in an inoculum concentration between 107 and 108 cfu/mL. The test solutions were inoculated for a 1 hour and a 3 hour exposure period, neutralized with DEB with 0.1% SLS added, and plated in duplicate.
- Results: One hour of peptide exposure at this concentration resulted in a dramatic biocidal effect particularly for SEQ ID NO. 1 and SEQ ID NO. 2. The three hour exposure time resulted in a similar, or slightly but not significantly greater effect. The results from the 1 hour exposure time are shown in the Table below. SEQ ID NO. 3 and SEQ ID NO. 4 at this concentration was effective only on P. aeruginosa, C. albicans, and F. solani, but had no effect on either S. aureus and S. marcescens. A one hour exposure to both of the other two peptides resulted in complete kill of all 5 organisms.
-
Average Test average Log Microorganism Solution ID dilution cfu cfu/mL Reduction S. aureus Positive −4 47 4.70E+05 (ATCC 6538) Controls P113 −4 61 6.10E+05 −0.11 P113D −4 47 4.70E+05 0.00 D4E1 −1 0 0.00E+00 >4.67 D2A21 −1 0 0.00E+00 >4.67 P. aeruginosa Positive −4 50 5.00E+05 (ATCC 9027) Controls P113 −1 6 6.00E+01 3.92 P113D −1 2 2.00E+01 4.40 D4E1 −1 0 0.00E+00 >4.70 D2A21 −1 0 0.00E+00 >4.70 S. marcescens Positive −4 60 6.00E+05 (ATCC 13880) Controls P113 −4 40 4.00E+05 0.18 P113D −4 28 2.80E+05 0.33 D4E1 −1 0 0.00E+00 >4.78 D2A21 −1 0 0.00E+00 >4.78 C. albicans Positive −4 86 8.60E+05 (ATCC 10231) Controls P113 −1 551 5.51E+03 2.19 P113D −2 33 3.30E+03 2.42 D4E1 −1 0 0.00E+00 >4.93 D2A21 −1 0 0.00E+00 >4.93 F. solani Positive −4 16 1.60E+05 (ATCC 36031) Controls P113 −2 60 6.00E+03 1.43 P113D −2 64 6.40E+03 1.40 D4E1 −1 0 0.00E+00 >4.20 D2A21 −1 0 0.00E+00 >4.20 Note: Neutralizer controls for all solutions passed specifications with all organisms indicating the the test results are valid. - Conclusion. The selectivity of SEQ ID NO. 3 on Candida and Pseudomonas may prove useful for certain applications. There was no significant difference between the SEQ ID NO. 3 (L) and SEQ ID NO. 4. The broad spectrum efficacy of SEQ ID NO. 1 and SEQ ID NO. 2 indicates that these peptides may prove extremely useful for treating a wide variety of ocular infections, and in particular, contact-lens associated keratitis.
- Purpose: To establish a dose-response curve for SEQ ID NO. 3, SEQ ID NO. 1, and SEQ ID NO. 2, focusing specifically on their effectiveness against bacteria.
- Method: The Disinfection Efficacy test was used as in experiment 2 using Staphylococcus aureus and Pseudomonas aeruginosa. The peptides were diluted in water at concentrations of 100, 33.3, 10, 3.33, and 1 ug/mL. The test solutions were inoculated for 1 hour, neutralized, and plated in duplicate.
- Results: Complete kill of P. aeruginosa resulted from concentrations as low as 1 ug/mL SEQ ID NO. 1 and SEQ ID NO. 2 and 3.33 ug/mL P-113. Complete kill S. aureus was achieved with 1 ug/mL SEQ ID NO. 1 and 3.33 ug/ml SEQ ID NO. 2. As expected from the results of Experiment 1, SEQ ID NO. 3 was not effective against S. aureus. Since the traditional logarhythmic response was not observed for most of these concentration series, the results are shown in tabular form below.
-
Test Solution Conc. cfu average Average Log Microorganism ID (μg/mL) dilution (average) cfu/mL Reduction S. aureus Positive −4 36 3.60E+05 ATCC 6538 Control T = 1 hr D4E1 100 −1 0 0.00E+00 >4.86 33 −1 0 0.00E+00 >4.86 10 −1 0 0.00E+00 >4.86 3.33 −1 0 0.00E+00 >4.86 1 −1 1 5.00E+00 4.86 D2A21 100 −1 0 0.00E+00 >4.86 33 −1 0 0.00E+00 >4.86 10 −1 1 1.00E+01 4.56 3.33 −1 0 0.00E+00 >4.86 1 −1 112 1.12E+03 2.51 P-113 100 −4 38 3.80E+05 −0.02 33 −4 34 3.40E+05 0.03 10 −3 202 2.02E+05 0.25 3.33 −3 144 1.44E+05 0.40 1 −3 60 5.95E+04 0.78 P. aeruginosa Positive initial −4 53.5 5.35E+05 ATCC 9027 Controls T = 1 hr D4E1 100 −1 0 0.00E+00 >5.03 33 −1 1 5.00E+00 5.03 10 −1 0 0.00E+00 >5.03 3.33 −1 0 0.00E+00 >5.03 1 −1 1 1.00E+01 4.73 D2A21 100 −1 0 0.00E+00 >5.03 33 −1 0 0.00E+00 >5.03 10 −1 0 0.00E+00 >5.03 3.33 −1 0 0.00E+00 >5.03 1 −1 0 0.00E+00 >5.03 P-113 100 −1 0 0.00E+00 >5.03 33 −1 0 0.00E+00 >5.03 10 −1 2 1.50E+01 4.55 3.33 −1 1 5.00E+00 5.03 1 −1 39 3.90E+02 3.14 Note: Neutralizer controls for all solutions passed specifications with all organisms indicating the the test results are valid. - Conclusion: Peptides SEQ ID NO. 1 and SEQ ID NO. 2 are extremely effective against the two bacterial species tested, indicating that both gram-positive and gram-negative bacteria might be suitable targets for therapeutic applications of these molecules. The low concentrations required for complete kill of 105 cfu/mL bacteria indicate that the therapeutic index (safety) might be very high, since concentrations of peptide as high as XXX/mL have been reported to be non-toxic in XXX cells.
Claims (20)
1. An ophthalmic solution comprising 0.001 to 10 weight percent of a peptide chosen from the group consisting of SEQ ID NO.1 and SEQ ID NO. 2; and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution is less than 0.2 percent by weight.
2. The solution of claim 1 , wherein said preservative agent is a cationic polymeric preservative having a concentration between 1 and 100 parts per million.
3. The solution of claim 1 , further comprising a physiologically compatible buffer selected from the group consisting of phosphate, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, Tris, MES, MOPS, PIPES, TAPS, TES, Glycine and Tricine.
4. The solution of claim 1 , further comprising between 0.01% and 5.0% glycerin.
5. The solution of claim 1 further comprising between 0.01% and 2.0% of decanedioic acid.
6. The solution of claim 1 further comprising a wetting agent selected from the group consisting of polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils.
7. The solution of claim 1 further comprising a sequestering agent selected from the group consisting as ethylenediaminetetraacetic acid, phosphonates, citrate, gluconate and tartarate.
8. The solution of claim 1 , wherein the concentration of chloride in said solution is not more than 0.2 mole percent.
9. The solution of claim 1 , wherein said solution has a pH between 6.0 and 8.0.
10. The solution of claim 2 , wherein said cationic polymeric preservative is polyhexamethylene biguanide.
11. A method for wetting a contact lens comprising the steps of:
providing a contact lens; and
contacting said contact lens with a solution comprising 0.001 to 10 weight percent of peptide chosen from the group consisting of SEQ ID NO. 1 and SEQ ID NO. 2; and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution not more than 0.2 percent by weight.
12. The method of claim 11 , wherein said preservative agent is a cationic polymeric preservative having a concentration between 1 and 100 parts per million.
13. The method of claim 12 , wherein said cationic polymeric preservative is polyhexamethylene biguanide.
14. The method of claim 11 , wherein said solution further comprises a physiologically compatible buffer selected from the group consisting of phosphate, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, Tris, MES, MOPS, PIPES, TAPS, TES, Glycine and Tricine.
15. The method of claim 11 , wherein said solution has a pH between 6.0 and 8.0.
16. A method for delivering an ophthalmic solution to the eye comprising the steps of:
providing a bottle comprising a solution comprising 0.001 to 10 weight percent of peptide chosen from the group consisting of SEQ ID NO. 1 and SEQ ID NO. 2; and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution not more than 0.2 percent by weight; and
delivering said solution form said bottle to an eye such that the solution comes in direct contact with corneal tissue.
17. The method of claim 16 , wherein said preservative agent is a cationic polymeric preservative having a concentration between 1 and 100 parts per million.
18. The method of claim 17 , wherein said cationic polymeric preservative is polyhexamethylene biguanide.
19. The method of claim 16 , wherein said solution further comprises a physiologically compatible buffer selected from the group consisting of phosphate, bicarbonate, citrate, borate, ACES, BES, BICINE, BIS, BIS-Tris, BIS-Tris Propane, HEPES, HEPPS, imidazole, Tris, MES, MOPS, PIPES, TAPS, TES, Glycine and Tricine.
20. The method of claim 16 , wherein said solution has a pH between 6.0 and 8.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/037,802 US20110212885A1 (en) | 2003-04-15 | 2011-03-01 | Ophthalmic and contact lens solutions containing peptides as preservative |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46294003P | 2003-04-15 | 2003-04-15 | |
PCT/US2004/011575 WO2004091438A2 (en) | 2003-04-15 | 2004-04-15 | Improved ophthalmic and contact lens solutions containing peptides as representative enhancers |
US59335207A | 2007-06-29 | 2007-06-29 | |
US13/037,802 US20110212885A1 (en) | 2003-04-15 | 2011-03-01 | Ophthalmic and contact lens solutions containing peptides as preservative |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/011575 Continuation WO2004091438A2 (en) | 2003-04-15 | 2004-04-15 | Improved ophthalmic and contact lens solutions containing peptides as representative enhancers |
US59335207A Continuation | 2003-04-15 | 2007-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110212885A1 true US20110212885A1 (en) | 2011-09-01 |
Family
ID=33300015
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/593,352 Active 2026-10-25 US7939501B2 (en) | 2003-04-15 | 2004-04-15 | Ophthalmic and contact lens solutions containing peptides as preservative |
US13/037,802 Abandoned US20110212885A1 (en) | 2003-04-15 | 2011-03-01 | Ophthalmic and contact lens solutions containing peptides as preservative |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/593,352 Active 2026-10-25 US7939501B2 (en) | 2003-04-15 | 2004-04-15 | Ophthalmic and contact lens solutions containing peptides as preservative |
Country Status (2)
Country | Link |
---|---|
US (2) | US7939501B2 (en) |
WO (1) | WO2004091438A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557868B2 (en) | 2000-11-04 | 2013-10-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions using low molecular weight amines |
US9492582B2 (en) * | 2000-11-08 | 2016-11-15 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
US7939501B2 (en) * | 2003-04-15 | 2011-05-10 | Smith Francis X | Ophthalmic and contact lens solutions containing peptides as preservative |
CA2655360C (en) | 2006-07-12 | 2014-09-16 | Novartis Ag | Actinically crosslinkable copolymers for manufacturing contact lenses |
AR064286A1 (en) | 2006-12-13 | 2009-03-25 | Quiceno Gomez Alexandra Lorena | PRODUCTION OF OPHTHALMIC DEVICES BASED ON POLYMERIZATION BY PHOTOINDUCIDED SCALE GROWTH |
TWI419719B (en) | 2007-08-31 | 2013-12-21 | Novartis Ag | Contact lens products |
US8689971B2 (en) | 2007-08-31 | 2014-04-08 | Novartis Ag | Contact lens packaging solutions |
US20130310327A1 (en) * | 2012-05-18 | 2013-11-21 | Rapid Pathogen Screening, Inc. | Histatin for Corneal Wound Healing and Ocular Surface Disease |
MY186090A (en) | 2015-12-03 | 2021-06-21 | Alcon Inc | Contact lens packaging solutions |
Citations (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976576A (en) * | 1956-04-24 | 1961-03-28 | Wichterle Otto | Process for producing shaped articles from three-dimensional hydrophilic high polymers |
US3429576A (en) * | 1965-08-28 | 1969-02-25 | Yoshiaki Ikeda | Golf club having level indicating means and weight means |
US3503393A (en) * | 1966-05-19 | 1970-03-31 | Blease Anaesthetic Equip Ltd | Patient controlled respiratory apparatus |
US3591329A (en) * | 1967-03-15 | 1971-07-06 | Ceskoslovenska Akademie Ved | Apparatus for preserving hydrophilic gels,more particularly ocular contact lenses |
US3689673A (en) * | 1970-11-10 | 1972-09-05 | Barnes Hind Pharm Inc | The process of soaking and sterilizing hydrophilic soft contact lenses with chlorhexidene |
US3755561A (en) * | 1971-03-22 | 1973-08-28 | Burton Parsons & Co Inc | Bactericidal contact lens solution |
US3873696A (en) * | 1972-01-31 | 1975-03-25 | Allergan Pharma | Cleaning and sterilizing soft contact lens |
US3876768A (en) * | 1972-11-06 | 1975-04-08 | Hydrophilics Int Inc | Sterilization of soft, hydrophilic acrylate and methacrylate copolymer materials |
US3888782A (en) * | 1972-05-08 | 1975-06-10 | Allergan Pharma | Soft contact lens preserving solution |
US3910296A (en) * | 1973-04-20 | 1975-10-07 | Allergan Pharma | Method of removing proteinaceous deposits from contact lenses |
US3911107A (en) * | 1972-12-18 | 1975-10-07 | Flow Pharma Inc | Iodine composition and dissipating solution |
US3912450A (en) * | 1971-06-21 | 1975-10-14 | Wave Energy Systems | Method for synergistic disinfection or sterilization |
US3943251A (en) * | 1973-06-27 | 1976-03-09 | Medow Norman B | Ophthamological use of hydrastis compounds |
US4022834A (en) * | 1972-03-16 | 1977-05-10 | A/S Farmaceutisk Industri | Antibacterially active hexamethylene-bis-biguanides |
US4029817A (en) * | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
US4046706A (en) * | 1976-04-06 | 1977-09-06 | Flow Pharmaceuticals, Inc. | Contact lens cleaning composition |
US4136175A (en) * | 1975-06-17 | 1979-01-23 | Burroughs Wellcome Co. | Purine nucleotide antiveral composition and methods of use |
US4136534A (en) * | 1976-05-19 | 1979-01-30 | Carlo Villa | Knitting machine |
US4209817A (en) * | 1978-03-15 | 1980-06-24 | Square D Company | Circuit breaker having an electronic fault sensing and trip initiating unit |
US4354952A (en) * | 1981-03-12 | 1982-10-19 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution comprising chlorhexidine and salts thereof |
US4361549A (en) * | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4361548A (en) * | 1980-11-28 | 1982-11-30 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution (polymeric) |
US4361458A (en) * | 1981-02-13 | 1982-11-30 | The Wurlitzer Company | Piano soundboard and method of making same |
US4394381A (en) * | 1979-04-13 | 1983-07-19 | George F. And Irene Sherrill 1978 Trust No. 1 | Method for the relief of pain |
US4439417A (en) * | 1980-11-14 | 1984-03-27 | Kao Soap Co., Ltd. | Shampoo composition |
US4525346A (en) * | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
US4599360A (en) * | 1983-08-10 | 1986-07-08 | Sankyo Company Limited | Ophthalmic anti-inflammatory agents |
USRE32672E (en) * | 1985-09-09 | 1988-05-24 | Allergan, Inc. | Method for simultaneously cleaning and disinfecting contact lenses using a mixture of peroxide and proteolytic enzyme |
US4748189A (en) * | 1985-04-19 | 1988-05-31 | Ciba-Geigy Corporation | Ophthalmic solutions and methods for improving the comfort and safety of contact lenses |
US4783488A (en) * | 1987-01-31 | 1988-11-08 | Bausch & Lomb Incorporated | Contact lens wetting solution |
US4820352A (en) * | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
US4826879A (en) * | 1986-01-31 | 1989-05-02 | Senju Pharmaceutical Co., Ltd. | Intraocular pressure lowering composition for topical use |
US4836986A (en) * | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US4863900A (en) * | 1987-01-15 | 1989-09-05 | The Research Foundation Of State University Of New York | Method for reducing viral transmission with poly-L-histidine |
US4891423A (en) * | 1989-03-20 | 1990-01-02 | Stockel Richard F | Polymeric biguanides |
US4894464A (en) * | 1980-01-21 | 1990-01-16 | Pfizer Inc. | Branched amides of L-aspartyl-D-amino acid dipeptides |
US4988710A (en) * | 1989-08-25 | 1991-01-29 | Washington University | Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins |
US4997626A (en) * | 1990-01-05 | 1991-03-05 | Allergan, Inc. | Methods to disinfect contact lenses |
US5030721A (en) * | 1988-02-18 | 1991-07-09 | Kikkoman Corporation | Novel N-acetyl-β-D-glucosamine derivatives and a process for production thereof as well as application to reagents for assaying N-acetyl-β-D-glucosaminidase activity |
US5078908A (en) * | 1989-10-02 | 1992-01-07 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
US5089261A (en) * | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5122354A (en) * | 1989-07-20 | 1992-06-16 | Tokai Denka Kogyo Kabushiki Kaisha | Histidine-hydrogen peroxide adduct and process for preparing same |
US5174872A (en) * | 1990-06-08 | 1992-12-29 | Technicon Instruments Corporation | Metal-free buffer for ion selective electrode-based assays |
US5175161A (en) * | 1989-04-06 | 1992-12-29 | Sankyo Company, Limited | Occular hypotensive agents |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5192535A (en) * | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
US5279673A (en) * | 1990-01-05 | 1994-01-18 | Allergan, Inc. | Methods to disinfect contact lenses |
US5300296A (en) * | 1989-11-06 | 1994-04-05 | Frank J. Holly | Antimicrobial agent for opthalmic formulations |
US5361287A (en) * | 1994-03-29 | 1994-11-01 | B&W Fuel Company | Nuclear fuel assembly lower end fitting |
US5439572A (en) * | 1991-12-02 | 1995-08-08 | Isoclear, Inc. | Lens protective encasement packet |
US5449658A (en) * | 1993-12-07 | 1995-09-12 | Zeneca, Inc. | Biocidal compositions comprising polyhexamethylene biguanide and EDTA, and methods for treating commercial and recreational water |
US5494937A (en) * | 1994-07-22 | 1996-02-27 | Alcon Laboratories, Inc. | Saline solution for treating contact lenses |
US5547990A (en) * | 1994-05-20 | 1996-08-20 | Lonza, Inc. | Disinfectants and sanitizers with reduced eye irritation potential |
US5591773A (en) * | 1994-03-14 | 1997-01-07 | The Trustees Of Columbia University In The City Of New York | Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters |
US5607681A (en) * | 1990-02-03 | 1997-03-04 | The Boots Company Plc | Anti-microbial compositions |
US5624958A (en) * | 1987-12-31 | 1997-04-29 | Isaacs; Charles E. | Disinfecting contact lenses |
US5660862A (en) * | 1990-12-19 | 1997-08-26 | Allergan | Compositions and methods for contact lens disinfecting |
US5661130A (en) * | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
US5674450A (en) * | 1994-04-28 | 1997-10-07 | Johnson & Johnson Medical, Inc. | Vapor sterilization using a non-aqueous source of hydrogen peroxide |
US5691379A (en) * | 1993-05-22 | 1997-11-25 | Asta Medica Aktiengesellschaft | Dihydrolipoic acid as an ophthalmological agent to suppress intolerance reactions in the area between implants and living body tissue |
US5718895A (en) * | 1995-11-16 | 1998-02-17 | Alcon Laboratories, Inc. | Enzymes with low isoelectric points for use in contact lens cleaning |
US5719110A (en) * | 1996-08-14 | 1998-02-17 | Allergan | Contact lens care compositions with inositol phosphate components |
US5741817A (en) * | 1994-07-22 | 1998-04-21 | Chowhan; Masood | Use of low molecular weight amino acids in ophthalmic compositions |
US5770582A (en) * | 1987-10-28 | 1998-06-23 | Pro-Neuron, Inc. | Pharmaceutical compositions containing deoxyribonucleosides for wound healing |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
US5807585A (en) * | 1988-08-04 | 1998-09-15 | Ciba Vision Corporation | Method of preserving ophthalmic solution and compositions therefor |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US5854303A (en) * | 1995-05-15 | 1998-12-29 | Allergan Sales, Inc. | Polymer, article and method for inhibiting the growth of ocular pathogens in eye care products |
US5869468A (en) * | 1994-04-04 | 1999-02-09 | Freeman; William R. | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs |
US5888950A (en) * | 1993-03-18 | 1999-03-30 | Wilmington Partners Lp | Alcohol-containing abrasive composition for cleaning contact lenses |
US5891733A (en) * | 1994-10-20 | 1999-04-06 | Toa Medical Electronics Co., Ltd. | Reagent for analyzing solid components in urine and method for analyzing solid components by employing the same |
US5925317A (en) * | 1996-01-22 | 1999-07-20 | Bausch & Lomb Incorporated | Dual neutralization system for iodine treatment of contact lenses |
US5925371A (en) * | 1996-12-18 | 1999-07-20 | Sumitomo Chemical Co., Ltd. | Arthropod repellent and method for repelling arthropods |
US5942218A (en) * | 1993-05-26 | 1999-08-24 | Fresenius Ag | Anti-infective material |
US5945446A (en) * | 1997-02-10 | 1999-08-31 | Laubc Biochemicals, Corporation | Process for preparing synthetic soil-extract materials and medicaments based thereon |
US5952320A (en) * | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
US5965738A (en) * | 1994-09-20 | 1999-10-12 | Wakunaga Seiyaku Kabushiki Kaisha | Process for producing N-biphenylmethylthiadiazoline derivative or salt thereof and intermediate for producing the same |
US6008195A (en) * | 1996-02-16 | 1999-12-28 | The Regents Of University Of California | Antimicrobial peptides and methods of use |
US6022732A (en) * | 1997-04-09 | 2000-02-08 | Allergan | Hydrogen peroxide destroying compositions and methods of using same |
US6056920A (en) * | 1997-12-12 | 2000-05-02 | Vertex Pharmaceuticals Incorporated | Process for identifying a solvent condition suitable for determining a biophysical property of a protein |
US6117869A (en) * | 1998-08-04 | 2000-09-12 | Warner-Lambert Company | Compounds for and methods of inhibiting matrix metalloproteinases |
US6121327A (en) * | 1998-05-22 | 2000-09-19 | Menicon Co., Ltd. | Contact lens disinfecting solution |
US6126706A (en) * | 1997-11-10 | 2000-10-03 | Tomey Corporation | Method of cleaning and disinfecting contact lens |
US6139646A (en) * | 1998-09-01 | 2000-10-31 | Alcon Laboratories, Inc. | Alkyl trypsin compositions and methods of use in contact lens cleaning and disinfecting systems |
US6153568A (en) * | 1997-11-12 | 2000-11-28 | Mccanna; David J. | Compositions comprising polyquaterniums in combination with polymeric biguanides for disinfecting contact lenses |
US6153563A (en) * | 1999-11-10 | 2000-11-28 | Lithchem International | Pouched ingredients for preparing greases |
US6162393A (en) * | 1998-08-06 | 2000-12-19 | Ndt, Inc. | Contact lens and ophthalmic solutions |
US6309658B1 (en) * | 1997-11-12 | 2001-10-30 | Bausch & Lomb Incorporated | Treatment of contact lenses with aqueous solution comprising a carbonate salt for enhanced cleaning |
US6309596B1 (en) * | 1998-12-15 | 2001-10-30 | Bausch & Lomb Incorporated | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine |
US6432893B1 (en) * | 1998-08-21 | 2002-08-13 | Senju Pharmaceutical Co., Ltd. | Method for removal of protein from contact lenses |
US6617291B1 (en) * | 2001-11-08 | 2003-09-09 | Francis X. Smith | Ophthalmic and contact lens solutions |
US6624203B1 (en) * | 2001-11-08 | 2003-09-23 | Francis X. Smith | Nucleic acid bases used in ophthalmic solutions |
US20030190258A1 (en) * | 2000-11-04 | 2003-10-09 | Smith Francis X. | Ophthalmic and contact lens solutions using low molecular weight amines |
US20050042198A1 (en) * | 1999-11-04 | 2005-02-24 | Smith Francis X. | Ophthalmic and contact lens wetting solutions |
US7939501B2 (en) * | 2003-04-15 | 2011-05-10 | Smith Francis X | Ophthalmic and contact lens solutions containing peptides as preservative |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO135634C (en) | 1972-03-16 | 1977-05-04 | Farmaceutisk Ind As | |
US4136173A (en) | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Mixed xanthan gum and locust beam gum therapeutic compositions |
JPS5810517A (en) | 1981-07-13 | 1983-01-21 | Santen Pharmaceut Co Ltd | Ophthalmic solution containing non-steroid antiphlogistic agent as main component |
JPH0672866B2 (en) * | 1986-03-19 | 1994-09-14 | 本田技研工業株式会社 | Oxygen concentration detector |
US4874850A (en) | 1986-08-07 | 1989-10-17 | Medice Chem.-Pharm. Fabrik Putter Gmbh & Co. | Pharmaceutical preparations |
WO1996025183A2 (en) * | 1995-02-17 | 1996-08-22 | Allergan, Inc. | Ophthalmic compositions including peptides and peptide derivatives and methods for using same |
US5965736A (en) | 1996-01-16 | 1999-10-12 | Lumigen, Inc. | Compositions and methods for generating red chemiluminescence |
JPH1059846A (en) | 1996-06-10 | 1998-03-03 | Kikkoman Corp | Preventive or remedy for cararacta |
RU2127100C1 (en) | 1997-04-17 | 1999-03-10 | Борзенок Сергей Анатольевич | Ocular drops "pyrotonik" |
US5925320A (en) * | 1997-06-04 | 1999-07-20 | Jones; John P. | Air purification system |
JPH11249087A (en) | 1997-12-18 | 1999-09-17 | Tome:Kk | Light agent for contact lens |
US6156563A (en) * | 1998-01-29 | 2000-12-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for clarifying cane sugar juice |
JP2000016965A (en) | 1998-06-29 | 2000-01-18 | Mitsubishi Gas Chem Co Inc | Production of hydroxyalkylacrylic ester or methacrylic acid ester modified with caprolactone |
US6550862B2 (en) * | 2001-06-14 | 2003-04-22 | Cosco Management, Inc. | Juvenile vehicle seat cup holder |
-
2004
- 2004-04-15 US US10/593,352 patent/US7939501B2/en active Active
- 2004-04-15 WO PCT/US2004/011575 patent/WO2004091438A2/en active Application Filing
-
2011
- 2011-03-01 US US13/037,802 patent/US20110212885A1/en not_active Abandoned
Patent Citations (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976576A (en) * | 1956-04-24 | 1961-03-28 | Wichterle Otto | Process for producing shaped articles from three-dimensional hydrophilic high polymers |
US3429576A (en) * | 1965-08-28 | 1969-02-25 | Yoshiaki Ikeda | Golf club having level indicating means and weight means |
US3503393A (en) * | 1966-05-19 | 1970-03-31 | Blease Anaesthetic Equip Ltd | Patient controlled respiratory apparatus |
US3591329A (en) * | 1967-03-15 | 1971-07-06 | Ceskoslovenska Akademie Ved | Apparatus for preserving hydrophilic gels,more particularly ocular contact lenses |
US3689673A (en) * | 1970-11-10 | 1972-09-05 | Barnes Hind Pharm Inc | The process of soaking and sterilizing hydrophilic soft contact lenses with chlorhexidene |
US3755561A (en) * | 1971-03-22 | 1973-08-28 | Burton Parsons & Co Inc | Bactericidal contact lens solution |
US3912450A (en) * | 1971-06-21 | 1975-10-14 | Wave Energy Systems | Method for synergistic disinfection or sterilization |
US3873696A (en) * | 1972-01-31 | 1975-03-25 | Allergan Pharma | Cleaning and sterilizing soft contact lens |
US4022834A (en) * | 1972-03-16 | 1977-05-10 | A/S Farmaceutisk Industri | Antibacterially active hexamethylene-bis-biguanides |
US3888782A (en) * | 1972-05-08 | 1975-06-10 | Allergan Pharma | Soft contact lens preserving solution |
US3876768A (en) * | 1972-11-06 | 1975-04-08 | Hydrophilics Int Inc | Sterilization of soft, hydrophilic acrylate and methacrylate copolymer materials |
US3911107A (en) * | 1972-12-18 | 1975-10-07 | Flow Pharma Inc | Iodine composition and dissipating solution |
US3910296A (en) * | 1973-04-20 | 1975-10-07 | Allergan Pharma | Method of removing proteinaceous deposits from contact lenses |
US3910296B1 (en) * | 1973-04-20 | 1987-04-14 | ||
US3943251A (en) * | 1973-06-27 | 1976-03-09 | Medow Norman B | Ophthamological use of hydrastis compounds |
US4029817A (en) * | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
US4136175A (en) * | 1975-06-17 | 1979-01-23 | Burroughs Wellcome Co. | Purine nucleotide antiveral composition and methods of use |
US4046706A (en) * | 1976-04-06 | 1977-09-06 | Flow Pharmaceuticals, Inc. | Contact lens cleaning composition |
US4136534A (en) * | 1976-05-19 | 1979-01-30 | Carlo Villa | Knitting machine |
US4209817A (en) * | 1978-03-15 | 1980-06-24 | Square D Company | Circuit breaker having an electronic fault sensing and trip initiating unit |
US4394381A (en) * | 1979-04-13 | 1983-07-19 | George F. And Irene Sherrill 1978 Trust No. 1 | Method for the relief of pain |
US4361549A (en) * | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4894464A (en) * | 1980-01-21 | 1990-01-16 | Pfizer Inc. | Branched amides of L-aspartyl-D-amino acid dipeptides |
US4439417A (en) * | 1980-11-14 | 1984-03-27 | Kao Soap Co., Ltd. | Shampoo composition |
US4361548A (en) * | 1980-11-28 | 1982-11-30 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution (polymeric) |
US4361458A (en) * | 1981-02-13 | 1982-11-30 | The Wurlitzer Company | Piano soundboard and method of making same |
US4354952A (en) * | 1981-03-12 | 1982-10-19 | Bausch & Lomb Incorporated | Contact lens disinfecting and preserving solution comprising chlorhexidine and salts thereof |
US4525346A (en) * | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
US4820352A (en) * | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
US4599360A (en) * | 1983-08-10 | 1986-07-08 | Sankyo Company Limited | Ophthalmic anti-inflammatory agents |
US4836986A (en) * | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US4748189A (en) * | 1985-04-19 | 1988-05-31 | Ciba-Geigy Corporation | Ophthalmic solutions and methods for improving the comfort and safety of contact lenses |
USRE32672E (en) * | 1985-09-09 | 1988-05-24 | Allergan, Inc. | Method for simultaneously cleaning and disinfecting contact lenses using a mixture of peroxide and proteolytic enzyme |
US4826879A (en) * | 1986-01-31 | 1989-05-02 | Senju Pharmaceutical Co., Ltd. | Intraocular pressure lowering composition for topical use |
US4863900A (en) * | 1987-01-15 | 1989-09-05 | The Research Foundation Of State University Of New York | Method for reducing viral transmission with poly-L-histidine |
US4783488A (en) * | 1987-01-31 | 1988-11-08 | Bausch & Lomb Incorporated | Contact lens wetting solution |
US5770582A (en) * | 1987-10-28 | 1998-06-23 | Pro-Neuron, Inc. | Pharmaceutical compositions containing deoxyribonucleosides for wound healing |
US5624958A (en) * | 1987-12-31 | 1997-04-29 | Isaacs; Charles E. | Disinfecting contact lenses |
US5192535A (en) * | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
US5030721A (en) * | 1988-02-18 | 1991-07-09 | Kikkoman Corporation | Novel N-acetyl-β-D-glucosamine derivatives and a process for production thereof as well as application to reagents for assaying N-acetyl-β-D-glucosaminidase activity |
US5807585A (en) * | 1988-08-04 | 1998-09-15 | Ciba Vision Corporation | Method of preserving ophthalmic solution and compositions therefor |
US5089261A (en) * | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US4891423A (en) * | 1989-03-20 | 1990-01-02 | Stockel Richard F | Polymeric biguanides |
US5175161A (en) * | 1989-04-06 | 1992-12-29 | Sankyo Company, Limited | Occular hypotensive agents |
US5122354A (en) * | 1989-07-20 | 1992-06-16 | Tokai Denka Kogyo Kabushiki Kaisha | Histidine-hydrogen peroxide adduct and process for preparing same |
US4988710A (en) * | 1989-08-25 | 1991-01-29 | Washington University | Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins |
US5078908A (en) * | 1989-10-02 | 1992-01-07 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
US5306440A (en) * | 1989-10-02 | 1994-04-26 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
US5300296A (en) * | 1989-11-06 | 1994-04-05 | Frank J. Holly | Antimicrobial agent for opthalmic formulations |
US5380303A (en) * | 1989-11-06 | 1995-01-10 | Frank J. Holly | Method for using an antimicrobial agent for ophthalmic formulations |
US5279673A (en) * | 1990-01-05 | 1994-01-18 | Allergan, Inc. | Methods to disinfect contact lenses |
US4997626A (en) * | 1990-01-05 | 1991-03-05 | Allergan, Inc. | Methods to disinfect contact lenses |
US5607681A (en) * | 1990-02-03 | 1997-03-04 | The Boots Company Plc | Anti-microbial compositions |
US5174872A (en) * | 1990-06-08 | 1992-12-29 | Technicon Instruments Corporation | Metal-free buffer for ion selective electrode-based assays |
US5660862A (en) * | 1990-12-19 | 1997-08-26 | Allergan | Compositions and methods for contact lens disinfecting |
US5439572A (en) * | 1991-12-02 | 1995-08-08 | Isoclear, Inc. | Lens protective encasement packet |
US5888950A (en) * | 1993-03-18 | 1999-03-30 | Wilmington Partners Lp | Alcohol-containing abrasive composition for cleaning contact lenses |
US5691379A (en) * | 1993-05-22 | 1997-11-25 | Asta Medica Aktiengesellschaft | Dihydrolipoic acid as an ophthalmological agent to suppress intolerance reactions in the area between implants and living body tissue |
US5942218A (en) * | 1993-05-26 | 1999-08-24 | Fresenius Ag | Anti-infective material |
US5661130A (en) * | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
US5449658A (en) * | 1993-12-07 | 1995-09-12 | Zeneca, Inc. | Biocidal compositions comprising polyhexamethylene biguanide and EDTA, and methods for treating commercial and recreational water |
US5591773A (en) * | 1994-03-14 | 1997-01-07 | The Trustees Of Columbia University In The City Of New York | Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters |
US5361287A (en) * | 1994-03-29 | 1994-11-01 | B&W Fuel Company | Nuclear fuel assembly lower end fitting |
US5869468A (en) * | 1994-04-04 | 1999-02-09 | Freeman; William R. | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs |
US5674450A (en) * | 1994-04-28 | 1997-10-07 | Johnson & Johnson Medical, Inc. | Vapor sterilization using a non-aqueous source of hydrogen peroxide |
US5547990A (en) * | 1994-05-20 | 1996-08-20 | Lonza, Inc. | Disinfectants and sanitizers with reduced eye irritation potential |
US5741817A (en) * | 1994-07-22 | 1998-04-21 | Chowhan; Masood | Use of low molecular weight amino acids in ophthalmic compositions |
US5494937A (en) * | 1994-07-22 | 1996-02-27 | Alcon Laboratories, Inc. | Saline solution for treating contact lenses |
US5965738A (en) * | 1994-09-20 | 1999-10-12 | Wakunaga Seiyaku Kabushiki Kaisha | Process for producing N-biphenylmethylthiadiazoline derivative or salt thereof and intermediate for producing the same |
US5891733A (en) * | 1994-10-20 | 1999-04-06 | Toa Medical Electronics Co., Ltd. | Reagent for analyzing solid components in urine and method for analyzing solid components by employing the same |
US5854303A (en) * | 1995-05-15 | 1998-12-29 | Allergan Sales, Inc. | Polymer, article and method for inhibiting the growth of ocular pathogens in eye care products |
US5718895A (en) * | 1995-11-16 | 1998-02-17 | Alcon Laboratories, Inc. | Enzymes with low isoelectric points for use in contact lens cleaning |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
US5925317A (en) * | 1996-01-22 | 1999-07-20 | Bausch & Lomb Incorporated | Dual neutralization system for iodine treatment of contact lenses |
US6008195A (en) * | 1996-02-16 | 1999-12-28 | The Regents Of University Of California | Antimicrobial peptides and methods of use |
US5719110A (en) * | 1996-08-14 | 1998-02-17 | Allergan | Contact lens care compositions with inositol phosphate components |
US5925371A (en) * | 1996-12-18 | 1999-07-20 | Sumitomo Chemical Co., Ltd. | Arthropod repellent and method for repelling arthropods |
US5952320A (en) * | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
US5945446A (en) * | 1997-02-10 | 1999-08-31 | Laubc Biochemicals, Corporation | Process for preparing synthetic soil-extract materials and medicaments based thereon |
US6022732A (en) * | 1997-04-09 | 2000-02-08 | Allergan | Hydrogen peroxide destroying compositions and methods of using same |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US6126706A (en) * | 1997-11-10 | 2000-10-03 | Tomey Corporation | Method of cleaning and disinfecting contact lens |
US6153568A (en) * | 1997-11-12 | 2000-11-28 | Mccanna; David J. | Compositions comprising polyquaterniums in combination with polymeric biguanides for disinfecting contact lenses |
US6309658B1 (en) * | 1997-11-12 | 2001-10-30 | Bausch & Lomb Incorporated | Treatment of contact lenses with aqueous solution comprising a carbonate salt for enhanced cleaning |
US6056920A (en) * | 1997-12-12 | 2000-05-02 | Vertex Pharmaceuticals Incorporated | Process for identifying a solvent condition suitable for determining a biophysical property of a protein |
US6121327A (en) * | 1998-05-22 | 2000-09-19 | Menicon Co., Ltd. | Contact lens disinfecting solution |
US6117869A (en) * | 1998-08-04 | 2000-09-12 | Warner-Lambert Company | Compounds for and methods of inhibiting matrix metalloproteinases |
US6162393A (en) * | 1998-08-06 | 2000-12-19 | Ndt, Inc. | Contact lens and ophthalmic solutions |
US6432893B1 (en) * | 1998-08-21 | 2002-08-13 | Senju Pharmaceutical Co., Ltd. | Method for removal of protein from contact lenses |
US6139646A (en) * | 1998-09-01 | 2000-10-31 | Alcon Laboratories, Inc. | Alkyl trypsin compositions and methods of use in contact lens cleaning and disinfecting systems |
US6309596B1 (en) * | 1998-12-15 | 2001-10-30 | Bausch & Lomb Incorporated | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine |
US20050042198A1 (en) * | 1999-11-04 | 2005-02-24 | Smith Francis X. | Ophthalmic and contact lens wetting solutions |
US6153563A (en) * | 1999-11-10 | 2000-11-28 | Lithchem International | Pouched ingredients for preparing greases |
US20030190258A1 (en) * | 2000-11-04 | 2003-10-09 | Smith Francis X. | Ophthalmic and contact lens solutions using low molecular weight amines |
US6617291B1 (en) * | 2001-11-08 | 2003-09-09 | Francis X. Smith | Ophthalmic and contact lens solutions |
US6624203B1 (en) * | 2001-11-08 | 2003-09-23 | Francis X. Smith | Nucleic acid bases used in ophthalmic solutions |
US7939501B2 (en) * | 2003-04-15 | 2011-05-10 | Smith Francis X | Ophthalmic and contact lens solutions containing peptides as preservative |
Also Published As
Publication number | Publication date |
---|---|
US7939501B2 (en) | 2011-05-10 |
WO2004091438A3 (en) | 2005-03-24 |
WO2004091438A2 (en) | 2004-10-28 |
US20080167246A1 (en) | 2008-07-10 |
WO2004091438B1 (en) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002227206B2 (en) | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers | |
US20110212885A1 (en) | Ophthalmic and contact lens solutions containing peptides as preservative | |
US5593637A (en) | Method and composition for disinfecting contact lenses | |
US6153568A (en) | Compositions comprising polyquaterniums in combination with polymeric biguanides for disinfecting contact lenses | |
US6369112B1 (en) | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol | |
AU2002227206A1 (en) | Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers | |
EP1733014B1 (en) | Cetylpyridinium chloride as an antimicrobial agent in ophthalmic compositions | |
US6617291B1 (en) | Ophthalmic and contact lens solutions | |
US6309596B1 (en) | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine | |
EP1603396B1 (en) | Antimicrobial compositions containing ethanolamine buffer and biguanide disinfectant | |
US10531663B2 (en) | Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers | |
US20020039975A1 (en) | Simplified process for cleaning and disinfecting contact lenses with a single solution | |
AU2014242073B2 (en) | Synergistic ophthalmic compositions for disinfecting contact lenses | |
IE920220A1 (en) | Method and composition for disinfecting contact lenses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |